Table 1 Relationship between SOST expression and clinical pathological features of patients with breast cancer

T stage

0.133

 T1

123 (29.15)

88 (71.54)

35 (28.46)

 T2

283 (67.06)

222 (78.45)

61 (21.55)

 T3

16 (3.79)

10 (62.50)

6 (37.50)

N stage

0.006

 N0-1

328 (77.73)

259 (78.96)

69 (21.04)

 N2–3

94 (22.27)

61 (64.89)

33 (35.11)

ER status

0.636

 ER negative

149 (35.31)

111 (74.50)

38 (25.50)

 ER positive

273 (64.69)

209 (76.56)

64 (23.44)

PR status

0.734

 PR negative

200 (47.39)

150 (5.00)

50 (25.00)

 PR positive

222 (52.61)

170 (76.58)

52 (23.42)

HER2 status

0.165

 HER2 negative

251 (59.48)

184 (73.31)

67 (26.69)

 HER2 positive

171 (40.52)

136 (79.53)

35 (20.47)

Ki67 status

0.570

 Ki67 < 20%

193 (45.73)

149 (77.20)

44 (22.80)

 Ki67 ≥ 20%

229 (54.27)

171 (74.67)

58 (25.33)

Molecular type

0.395

 HR + HER2-

188 (44.55)

140 (74.47)

48 (25.53)

 HR + HER2 + 

95 (22.51)

77 (81.05)

18 (18.95)

 HR-HER2 + 

76 (18.01)

59 (77.63)

17 (22.37)

 TNBC

63 (14.93)

44 (69.84)

19 (30.16)

Distant metastasis^a

 < 0.001

 No

272 (64.45)

227 (83.46)

45 (16.54)

 Yes

150 (35.55)

93 (62.00)

57 (38.00)

Bone metastasis

 < 0.001

 No

313 (74.17)

254 (81.15)

59 (18.85)

 Yes

109 (25.83)

66 (60.55)

43 (39.45)

Lung metastasis

0.282

 No

374 (88.63)

287 (76.74)

87 (23.26)

 Yes

48 (11.37)

33 (68.75)

15 (31.25)

Liver metastasis

0.155

 No

397 (94.08)

304 (76.57)

93 (23.43)

 Yes

25 (5.92)

16 (64.00)

9 (36.00)

Brain metastasis

0.686

 No

414 (98.10)

313 (75.60)

101 (24.40)

 Yes

8 (1.90)

7 (87.50)

1 (12.50)

Menopause status

0.300

 Premenopausal

172 (40.76)

135 (78.49)

37 (21.51)

 Postmenopausal

250 (59.24)

185 (74.00)

65 (26.00)